Nanjing Sanhome Pharmaceutical

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 3
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 1
CD47 and PD-L1Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
February 2028 (1)
Rilertinib (SH-1028)Phase 3Non-small Cell Lung Cancer
Est. primary completion 2028-02-01 · NCT06080776 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.